Camargo Invests in High-Level IT System To Increase Accessibility and Preserve Client Data - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Camargo Invests in High-Level IT System To Increase Accessibility and Preserve Client Data

Source: Company News Release
Camargo Pharmaceutical Services recently completed an extensive IT system update to offer its clients improved data availability, security, storage and redundancy. The new system is an important investment to Camargo’s infrastructure, allowing the full-service development partner to add value for its clients.

With these improvements, Camargo provides each of its national and international clients with an individual website including large-scale data storage availability, document management with version control, a superior level of security with minimal interruptions and 24/7 rapid access. The system also includes data retention and preservation for at least 20 years — exceeding the FDA’s and global regulatory agencies’ minimum data preservation requirements.

“Implementing enhanced data access and storage capacity are examples of the strides Camargo is making to broaden our service line, support our clients from concept through commercialization and grow our client base internationally,” said Jim Beach, chief operating officer for Camargo. “Data and its preservation are the lifeblood of product development programs and this new system supports our critical role as stewards of our clients’ data.”

To learn more about Camargo’s service offerings, visit camargopharma.com.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here